Clinical Evidence - Automated Insulin Delivery

ATTD 2025 - Dexcom CGM: All Ages All Stages of Diabetes

Yes

Related Resources

Podcast Episode 24: Type 2 Diabetes Management Through Glucose Tracking

Premium Content

Introducing Dexcom's Digital Health Hub

alexa.stelzer — Mon, 10 Feb 2025 16:38:04 +0000

Introducing Dexcom's Digital Health Hub

03/10/2025

alexa.stelzer Mon, 02/10/2025 - 16:38

A New Way to Discover Connected Health Apps

Dexcom’s Digital Health Ecosystem

Dexcom Continuous Glucose Monitoring (CGM) Systems connect to more insulin pumps, pens, and digital health apps than any other CGM brand.¹In fact, Dexcom's growing ecosystem consists of 90+ partners, including over 50 digital health apps.^*1

By seamlessly integrating Dexcom CGM data, connected apps provide patients with greater convenience and enhanced options for utilizing their glucose data. They can also give healthcare providers a more comprehensive view of patient health.

Studies have shown that Dexcom CGM connected with digital health apps can help increase time in range.^{2, 3,4, 5}

Given these benefits, it's not surprising that health apps are used by a large number of patients. 58% of patients with type 1 diabetes and 40% of patients with type 2 diabetes who own a smartphone use a health app to manage their condition.⁶

The widespread adoption and proven benefits of digital health apps underscore a significant opportunity for healthcare providers to integrate these tools into their clinical practice.

The Digital Health Hub

In response to feedback from both patients and healthcare providers, Dexcom developed a new Digital Health Hub that simplifies the process of finding the right diabetes management apps.

This new “digital hub” offers multiple ways for users to browse and find connected health apps. Users can use the search function to find apps or filter by category.

Categories include:

Product Type: Dexcom G6 or Dexcom G7
Operating System: iOS, Android, or Web
App Features: Data sharing, log meals/nutrition, track activity/exercise, and motivation

By filtering through the vast array of available options, users can quickly find the apps that meet their specific needs.

Explore connected apps

Dexcom’s Digital Health Hub is a valuable resource for healthcare providers and their patients. By exploring connected apps, providers can help patients create a personalized, integrated, and convenient diabetes management plan.

Explore the Digital Health Hub

^{*To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit}^{dexcom.com/integrate}^.

^References

^{1. Dexcom, data on file. 2024}

^{2. Akulova M, et al. Medical Research Archives. 2023;11(7.1):1-11.
3. Ahmadi F, et al. J Diabetes Sci Technol. 2024:19322968231223759.
4. Kannenberg S, et al. J Diabetes Sci Technol. 2024;19322968241266821.
5. MacColl S, et al. Youth with T1D Improve TIR by use of a relational agent embedded in a smart phone app, Poster presented at: ATTD 2024; March 6-9, 2024. Florence, Italy.}

^{6. dQ&A Digital Health Insights Report H1 2022.}

^MAT-7711

2025 Standards of Care in Diabetes Infographic

Related Resources

Podcast Episode 12: The Role of Digital Health in Diabetes Management

Premium Content

Off

New Episodes Alert: Beyond the Bolus Podcast

alexa.stelzer — Mon, 30 Sep 2024 21:36:43 +0000

New Episodes Alert: Beyond the Bolus Podcast

10/01/2024

alexa.stelzer Mon, 09/30/2024 - 21:36

Explore Innovations in Diabetes Technology with Omnipod’s Beyond the Bolus Podcast

Discover the latest episodes of Omnipod’s Beyond the Bolus podcast! Featuring expert insights on Omnipod 5 and Dexcom G7 integration with Dr. Pablo Mora, and the future of Type 2 diabetes care with Dr. Viral Shah. Stay ahead with actionable advice and industry trends. Listen now to enhance your practice!

We are thrilled to announce the release of brand-new episodes of Beyond the Bolus, Omnipod’s podcast tailored for healthcare professionals. These episodes feature healthcare providers from a variety of backgrounds and specialties and explore the latest in diabetes technology, clinical data and more. Recent episodes include:

Omnipod 5 with Dexcom G7 Integration is Here!: Join Dr. Pablo Mora as he delves into the seamless integration of Omnipod 5 with Dexcom G7. Learn about the benefits of this integration and how it can simply diabetes management for your patients.
Unlock the Future of Type 2 Diabetes Care: Dr. Viral Shah shares his insights on the evolving landscape of type 2 diabetes care. Discover emerging trends, innovative treatments, and strategies to improve patient outcomes.

Whether you’re looking to stay ahead of the latest trends or seeking practical advice from industry leaders, these episodes are packed with valuable content to enhance your practice.

Stay connected, stay informed, and continue to provide the best care for your patients with Beyond the Bolus.

Listen here or using the player below.

Podcast

Diabetes Technology

Clinical Evidence - Type 2 Diabetes

Related Resources

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters

Premium Content

Off

Glooko Enhances Transmitters for Direct Uploads from All Dexcom Receivers

alexa.stelzer — Wed, 18 Sep 2024 14:37:56 +0000

Glooko Enhances Transmitters for Direct Uploads from All Dexcom Receivers

09/20/2024

alexa.stelzer Wed, 09/18/2024 - 14:37

Glooko, a leader in remote patient monitoring, has released an update enabling their transmitters to directly upload data from all Dexcom receivers, including the G6, G7, Dexcom ONE, and Dexcom ONE+. This enhancement allows clinics using Glooko Transmitters to prescribe the latest Dexcom devices, ensuring seamless data uploads to Glooko patient files. This update is available in all regions where both Glooko and Dexcom devices are supported.

Additional Information for Healthcare Providers

This latest update adds to the extensive range of benefits Glooko offers to healthcare providers, including the ability to:

Sync data from a variety of devices: Glooko integrates data from a variety of diabetes devices, including glucose meters, insulin pumps, and continuous glucose monitors (CGMs). This ensures that all relevant patient information is available in one place1.
Remote Monitoring and Telehealth: The platform supports remote patient monitoring (RPM), allowing providers to manage patients’ progress both in-clinic and remotely1.
Increase overall efficiency: By reducing the time and effort required for data entry and analysis, healthcare providers can focus more on patient care.
EHR Integration: Glooko offers direct integration with Electronic Health Records (EHR) systems. Providers can access Glooko patient accounts directly from within the EHR, attach diabetes data to patient records, and deliver discrete data into the EHR flowsheet2.
Security and Compliance: Glooko places a strong emphasis on data privacy and compliance with healthcare regulations. The platform ensures that patient data is secure and adheres to all relevant healthcare standards1.
Clinical Evidence and Impact: Numerous clinical studies have demonstrated the effectiveness of Glooko in diabetes management. These studies highlight improved patient outcomes, increased adherence to treatment plans, and better overall diabetes control. Healthcare providers who have implemented Glooko report significant improvements in patient care and data integration3.

Glooko continues to lead the way in diabetes management with its innovative platform and commitment to improving patient care. The latest update, enabling direct uploads from all Dexcom receivers, further enhances the platform’s capabilities and offers significant benefits for healthcare providers.

Learn More About Glooko

Read more about how healthcare providers can benefit from Glooko, at https://glooko.com/providers/ or connect with Glooko Customer Support at support@glooko.com.

For additional questions about Glooko’s integration with Dexcom, reach out to Dexcom’s Partner Advisory Council at PAC@dexcom.com.

Footnotes/citations:
_1._{Glooko Connected Care Solution for Providers}

_2._{Glooko Connected Care Products for Providers}

_3._{Glooko Connected Care for Diabetes and Related Chronic Conditions}

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

Related Resources

Podcast Episode 13: Beta Bionics iLet

Premium Content

Off

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

OlgaDalisay — Wed, 19 Jun 2024 01:25:03 +0000

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

06/21/2024

OlgaDalisay Wed, 06/19/2024 - 01:25

Insulet has announced two important innovations for their Ominpod® 5 automated insulin delivery (AID) system:

Omnipod 5 integration with Dexcom G7 Sensor: This new feature will become broadly available over the coming months.
Omnipod 5 App for iPhone with Dexcom G6 recently started a limited market release with availability expected later this year.

The Omnipod 5 system’s integration with the Dexcom G7 requires a new Pod, one which is compatible with both the Dexcom G6 and G7 sensors.

Important Information for Starting Patients on Omnipod 5 with Dexcom G7 Sensor:

This Pod will have the same National Drug Code (NDC) as current Pods, which minimizes burden on clinic staff and means patients with Dexcom G6 insurance coverage for Pods will have Dexcom G7 insurance coverage for Pods. However, building up inventory of this new Pod in retail pharmacies across the nation will take some time. For access, please see the information below.

For Patients Currently Using Multiple Daily Injections (MDI) or Tubed Pumps:

To initiate a patient on the Dexcom G7, prescribe the Omnipod 5 Intro Kit and Pods exclusively through ASPN Pharmacies. ASPN will ensure new Omnipod patients receive the Dexcom G6/G7 compatible Pods.
Detailed instructions are available here on how to prescribe Omnipod 5 with Dexcom G7.

For Current Omnipod 5 Patients:

No new Pod prescription or prior authorization is required for patients already using Omnipod 5.
Existing Omnipod 5 users will receive a free software update the week of July 29th, enabling them to pair a Dexcom G7 with a compatible Pod. Patients will be notified when the update is available, along with detailed instructions.
Advise patients to continue using their Dexcom G6 supplies until they receive Pods labeled "Compatible with Dexcom G7" on their refill box.
Once patients see the "Compatible with Dexcom G7" label, prescribe the Dexcom G7 sensor.

iPhone Control with Omnipod 5 and Dexcom G6 Sensor:

The Omnipod 5 App for iPhone will initially launch with the Dexcom G6 sensor. Therefore, current patients preferring iPhone control should continue using the Dexcom G6 sensor.
For new patients desiring iPhone control, prescribe Omnipod 5 with Dexcom G6 as usual.

These updates aim to enhance patient care by integrating the latest technology seamlessly into the Omnipod 5 system.

Please review this information carefully and ensure your patients are informed of these exciting advancements.

For more information on the latest clinical evidence on the use of a tubeless insulin delivery system, check out this Research Spotlight article

For more information about these updates, visit Omnipod’s FAQs: G7 FAQs and iPhone FAQs.

© 2024 Insulet Corporation. Omnipod, and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Dexcom, Dexcom G6, and Dexcom G7 are registered trademarks of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

New Episodes Alert: Beyond the Bolus Podcast

Training Materials

Related Resources

Two Years with a Tubeless Automated Insulin Delivery System

Premium Content

Revolutionizing Diabetes Care: Advances in Automated Insulin Delivery Systems

OlgaDalisay — Wed, 19 Jun 2024 01:22:13 +0000

Revolutionizing Diabetes Care: Advances in Automated Insulin Delivery Systems

06/21/2024

OlgaDalisay Wed, 06/19/2024 - 01:22

The iLet Bionic Pancreas is designed to simplify and enhance glucose management. This automated insulin delivery (AID) system leverages advanced algorithms to deliver insulin doses tailored to the user's needs. By continuously monitoring glucose levels and adjusting insulin delivery in real-time, the iLet Bionic Pancreas aims to improve glycemic control and reduce the burden of diabetes management for patients.

Beat Bionics announced new updates for the iLet Mobile App - an integral component of the iLet Bionic Pancreas system that provides users with seamless and intuitive access to their diabetes management data.

Patients can now monitor their status conveniently through the app without needing to access their iLet device directly. However, please advise them to keep their alarms active, as these will only be displayed on the iLet device.

NEW iLet Mirror Display

The iLet Mobile App now allows patients to view their iLet home screen in real time on their smartphones. The app displays:

CGM glucose levels and trends
Insulin cartridge level
Battery level
Charts for the past 24 hours of CGM data and insulin dosing

NEW Pause Insulin Feature

The iLet system now includes a feature that enables patients to pause insulin delivery during activities such as showering, exercising, or swimming, preventing insulin wastage when disconnected from the device. Please ensure your patients are aware of the following:

They will be prompted to set a timer to remind them to resume insulin delivery.
An Insulin Paused banner will appear on the home screen when insulin delivery is paused.
After completing the activity, patients can resume insulin by tapping the Insulin Paused banner on the home screen or the Pause Insulin icon in the iLet Menu screen, then selecting Resume Delivery.
The iLet will remind them to resume insulin delivery after the timer expires, and they can resume directly from the reminder alert.

Secondary Target (formerly known as CGM Sleep Target)

The iLet device allows patients to set two different CGM targets over a 24-hour period. We recommend discussing with your patients before they make any adjustments to their CGM targets.

Please guide your patients through the update process for the iLet Mobile App to ensure they benefit from these new features. Click below for the instructions on how to update the app

How to update

^{Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at}^{https://www.betabionics.com/resources/user-guides/}^{or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to}^{www.betabionics.com/resources/safety}

^{DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.}

Podcast Episode 13: Beta Bionics iLet

Training Materials

Related Resources

Premium Content

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

OlgaDalisay — Tue, 21 May 2024 17:32:55 +0000

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

05/24/2024

OlgaDalisay Tue, 05/21/2024 - 17:32

A perspective from the United Kingdom

^{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

This short presentation was delivered during the recent ATTD Diabetes Congress in Italy.

Managing diabetes during pregnancy is critical for maternal and fetal health. Pregnancy induces physiological changes that affect insulin sensitivity, complicating glycemic control.¹ Poorly managed diabetes can lead to adverse outcomes such as preeclampsia, preterm birth, and congenital malformations.² Utilizing continuous glucose monitoring (CGM) technology allows for real-time glucose tracking, facilitating tighter glycemic control.³ This proactive management is essential in minimizing hyperglycemia and hypoglycemia, thus improving both maternal and neonatal outcomes.⁴ Close monitoring and interdisciplinary care are vital for optimizing pregnancy outcomes in women with diabetes.⁵

Dr Helen Murphy is a Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia, and a practicing clinician (Norfolk & Norwich University Hospital NHS Trust), Norwich, UK.

She runs a diabetes pregnancy research program which aims to support women with diabetes to achieve the pregnancy glucose targets required for optimal mother and baby health outcomes. She co-led the CONCEPTT Continuous Glucose Monitoring (CGM) trial. CONCEPTT demonstrated health benefits for mothers with type 1 diabetes (T1D), their newborn infants and the potential for substantial healthcare cost savings. In addition to scientific contributions, building research infrastructure and supporting the next generation of clinical academics, data from CONCEPTT led to international changes in clinical practice, CGM is now the recognized standard of care for pregnant women with T1D.

In this short ~20 min presentation, Dr Murphy will talk about the specifics of diabetes management in pregnant individuals across the United Kingdom, including:

National Diabetes in Pregnancy Audit
CGM use before and during Type 1 diabetes pregnancy
AiDAPT randomized trial results

^{Catalano, P. M., & Tyzbir, E. D. (1991). Effects of pregnancy on insulin sensitivity and beta-cell function in women with and without gestational diabetes.}^{American Journal of Obstetrics and Gynecology}^{, 165(3), 579-585.}
^{Reece, E. A., Leguizamon, G., & Wiznitzer, A. (2009). Gestational diabetes: the need for a common ground.}^{The Lancet}^{, 373(9677), 1789-1797.}
^{Voormolen, D. N., de Wit, L., van Rijn, B. B., Koster, M. P., de Valk, H. W., & Franx, A. (2018). Continuous glucose monitoring during pregnancy: An overview of recent studies.}^{Journal of Diabetes Science and Technology}^{, 12(5), 955-960.}
^{Murphy, H. R., et al. (2008). Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial.}^BMJ^{, 337, a1680.}
^{Yogev, Y., & Langer, O. (2008). Pregnancy outcome in diabetic patients.}^{Best Practice & Research Clinical Obstetrics & Gynaecology}^{, 22(6), 1041-1057}

Expert Presentations

Expert Presentations - Automated Insulin Delivery

Expert Presentations - Data Interpretation

Pregnancy

Premium Content

Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and DKA Than Historical Data

alexa.stelzer — Fri, 19 Apr 2024 17:38:27 +0000

Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and DKA Than Historical Data

04/26/2024

alexa.stelzer Fri, 04/19/2024 - 17:38

Results of the Control-IQ Observational (CLIO) Prospective Study

Research Spotlight

Graham R, Mueller L, Manning M, et al. Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi:10.1089/dia.2023.0341

Background

Individuals on intensive insulin therapy (IIT) face an elevated risk of experiencing Severe Hypoglycemia (SH) and Diabetic Ketoacidosis (DKA). It is important to minimize the occurrence of these adverse events (AE), when possible. Automated Insulin Delivery (AID) systems may help reduce some of these events.

Purpose of Study

To assess the safety and effectiveness of the Tandem t:slim X2 insulin pump with Control-IQ technology in the real-world outpatient setting over 12 months of use.

Participant Demographics (n = 3157)

Single-arm, prospective, fully virtual, longitudinal study

T1D
At least 6 years old
Control IQ & Dexcom G6 for 12 months
Virtual check-in and data uploads

Study Outcomes Measured

The primary outcomes measured were:

Incidence rates of SH and SKA
Safety of the automatic population of CGM readings into the bolus calculator when Control-IQ technology was in use
Glycemic outcomes as a measure of efficacy of the system
Patient-reported satisfaction with and trust in the system, diabetes impact, and sleep quality of Control-IQ with Dexcom CGM technology users.

Main Outcomes

SH and DKA rates were lower for users of t:slim X2 with Control-IQ with Dexcom CGM compared to historical data^§ for both adults and children.
Average time in range was >70% for adults and >60% for children, both groups achieving international consensus guidelines¹
42% reported a decrease of diabetes impact on quality of life^†
25% increase in device satisfaction^‡in both participants transitioning to Control-IQ from a different pump system and for participants transitioning from MDI therapy

Key Takeaways for t:slim X2 with Control IQ and Dexcom CGM

Lower observed rates of adverse events occurred independent of baseline A1C or prior insulin delivery method²
Control-IQ with Dexcom CGM technology is associated with a lower rate of severe hypoglycemia (compared to historical data)²
The study also indicates a lower rate of diabetic ketoacidosis in individuals using Control-IQ with Dexcom CGM technology compared to historical data²
Reduction in diabetes burden was consistently reported²

*Mean (SD) AE rates per 100 patient years for study participants as self-reported on monthly surveys through 12 months of Control-IQ technology use, compared to historical rates

AE = Adverse events

† Diabetes Impact median score was 4.75 (3.25–6.0) at baseline and 2.75 (2.0–4.0) at 12 months (P < 0.01).

‡ DIDS Device Satisfaction median score increased from 7.29 (5.57–8.71) at baseline to 9.14 (8.29–9.71) at 12 months

§ Data from T1D Exchange Registry

References

Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028
Graham R, Mueller L, Manning M, et al. Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi:10.1089/dia.2023.0341

Research Spotlight

Training Resources

dexcom-infographic-aid-clio-study-mat2235-v1 (4).pdf

Country

United States

Yes

Premium Content

Two Years with a Tubeless Automated Insulin Delivery System

alexa.stelzer — Fri, 19 Apr 2024 14:36:44 +0000

Two Years with a Tubeless Automated Insulin Delivery System

04/19/2024

alexa.stelzer Fri, 04/19/2024 - 14:36

A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes

Research Spotlight

Criego AB, Carlson AL, Brown SA, et al. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364

Background

Many people living with Type 1 diabetes (T1D) are struggling to achieve desired glycemic targets. Fortunately, Automated Insulin Delivery (AID) Systems have displayed promising outcomes in improving glycemic metrics.

Purpose of Study

To evaluate long-term safety and effectiveness of Omnipod® 5 AID system with Dexcom CGM in people with T1D during up to 2 years of use. This study is an extension of a 3-month outpatient pivotal clinical trial.

Participant Demographics (n = 224)

Extension phase of the single-arm, multicenter, pivotal trial.

T1D
A1C < 10%
Children (6-13.9 yo)
Adolescents/adults (14-70 yo)
Omnipod 5 & Dexcom G6 for 15 months
Sensor & glucose data collected for 2 years

Study Outcomes Measured

Primary effectiveness outcomes were:

Differences in A1C during the extension phase compared to baseline (before Omnipod 5)
Percentage of time in glucose target range² (TIR) during the extension phase compared to the standard therapy phase.

Primary safety outcomes were:

Incidence rates of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA).

Main Outcomes

Both age cohorts saw significant improvements in glycemic outcomes, mainly A1C and TIR1, from baseline throughout the extension phase.

A1C decreased from 7.7% to 7.2% in peds, and 7.2% to 6.9% in adolescents/adults
TIR increased from 54.2% to 65.9% in peds, and 63.6% to 72.9% in adolescents/adults
No incidents of SH or DKA reported in adult cohort during the extension phase²
96% median time spent in automation mode² in both cohorts of participants using Omnipod 5 and Dexcom CGM

Adverse Events

7 SH events - all occurred in children and unrelated to the study device
1 DKA event - suspected infusion set failure in a child

Key Takeaways for Omnipod® 5 and Dexcom CGM

Effectiveness of Omnipod 5 system with Dexcom CGM† was maintained in both children and adults for up to 2 years of at home use²
Longest prospective follow-up study to date on the use of an AID system with Dexcom CGM²
Rates of AE remained low in both cohorts, and improvements in glycemic control was maintained, supporting long-term benefits from AID use

† This study was conducted using Omnipod 5 and Dexcom G6 Continuous Glucose Monitoring System

References

Criego AB, Carlson AL, Brown SA, et al. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364
Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028

Research Spotlight

Podcast Episode 14: A Dynamic Duo: Dexcom & Omnipod

Training Resources

Country

United States

Related Resources

Premium Content

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

OlgaDalisay — Tue, 27 Feb 2024 19:37:55 +0000

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

02/27/2024

OlgaDalisay Tue, 02/27/2024 - 19:37

Despite advancements, many individuals with T1D struggle to maintain optimal glycemic control. Automated insulin delivery (AID) systems, particularly hybrid closed-loop (HCL) systems, aim to improve control and reduce burden by automating insulin delivery based on continuous glucose monitoring (CGM) data.

In this Research Spotlight we are highlighting a recent study:

Peacock, S., Frizelle, I. & Hussain, S. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Ther 14, 839–855 (2023). https://doi.org/10.1007/ s13300-023-01394-5

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Studies focusing on single-hormone commercial hybrid AID systems, involving participants with T1D, and reporting endpoints related to glycemic control were included.

The following endpoints were the main focus of the review:

Participants with T1D
A1c levels
Diabetic ketoacidosis (DKA) events
% of Time in Range (TIR) / Change in TIR
Incidents of severe hypoglycemia

Commercial HCL systems effectively improve TIR and glycemic control in T1D, with minimal risk of severe hypoglycemia.

Studies showed that HCL systems generally improved time in range (TIR) and glycemic control without increasing severe hypoglycemia. Psychosocial outcomes, such as quality of life and treatment satisfaction, were generally positive.

Results (Glycemic Outcomes)

Commercial HCL AID Systems are effective and can improve TIR³
Improvements in glycemic control were shown without increasing the incidence of severe hypoglycemia
Glycemic outcomes supported by real-world studies and randomized control trials (psychosocial endpoints analyzed separately - showing generally positive outcomes, but more data needed)

Research Spotlight

Training Materials - Downloads

Training Materials